GHK
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Not FDA-approved
A naturally occurring copper-binding tripeptide marketed for wound healing, skin anti-aging, and anti-inflammatory effects via switching on thousands of genes in damaged tissue. Strongest evidence is animal and lab work on the copper-bound form (GHK-Cu); GHK alone has almost no human trials, no long-term safety data, and no established dosing. Supply is unregulated. Not an FDA-approved drug.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
GHK (glycyl-histidyl-lysine) is a naturally occurring human tripeptide first isolated from blood plasma in 1973 by Loren Pickart. It is the base peptide form — without copper — that serves as the precursor to GHK-Cu. Present in your blood at about 200 ng/mL at age 20 and declining to roughly 80 ng/mL by age 60, this age-related drop correlates with reduced healing and regenerative capacity. GHK is also released from structural proteins like collagen during tissue injury, functioning as the body's natural "damage signal" that triggers repair processes.
How it works in the body
Binds copper and acts as a signaling molecule that resets gene expression in damaged tissue. It activates genes for collagen synthesis, anti-inflammatory cytokines, and stem cell markers while suppressing genes linked to inflammation and tissue destruction. Over 4,000 genes respond to GHK-Cu.
Research overview
GHK has been studied for over 50 years since Pickart's 1973 discovery that a factor in human blood albumin caused old liver tissue to produce proteins like younger tissue. Research expanded dramatically after 2010 when Broad Institute gene analysis revealed that GHK modulates expression of at least 4,000 human genes — roughly 31% of the genome — spanning pathways involved in tissue repair, inflammation, and remodeling. While most clinical studies used the copper-bound form (GHK-Cu), gene expression data and some lab studies show that GHK alone retains significant biological activity through gene-regulation pathways independent of copper. Animal studies show cognitive improvement in aged mice treated with GHK and anti-anxiety effects in rats. The peptide is considered very safe with no adverse events reported across decades of use in cosmetic and wound-healing products. However, the majority of human clinical evidence pertains to GHK-Cu rather than GHK alone.
Who researches GHK?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People exploring anxiety and stress management
Researched for anxiolytic or stress-reducing properties.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(8)
Rated by level of concern
Very limited human clinical data for GHK alone (most studies use GHK-Cu copper complex)
HighPMID 17147644; PMID 26236730 (review)
Research-grade GHK peptide may not meet pharmaceutical purity standards — quality varies among unregulated products sold online
ModerateFDA 503A Bulk Drug Substances review - peptide substances placed in Category 2 (fda.gov); general market observation, no GHK-specific publication
Sensitive to carboxypeptidase degradation, particularly in wound environments — rapid breakdown limits bioavailability
ModeratePharm Dev Technol 2016;21(2), physicochemical characterization of native GHK (doi:10.3109/10837450.2014.979944); PMID 26236730 (review)
Long-term systemic safety data in humans is lacking (no large-scale injectable trials)
HighAbsence of evidence on ClinicalTrials.gov and PubMed - registered GHK/GHK-Cu studies are small and topical
Gene modulation data is primarily from Broad Institute Connectivity Map computational analysis, not all validated in vivo
HighPMID 22937864 (Genome Med 2012, the CMap/fibroblast validation study); PMID 29986520 (Int J Mol Sci 2018 review)
GHK alone may have reduced efficacy compared to GHK-Cu for applications requiring copper delivery (antioxidant, wound healing)
ModeratePMID 26236730 (review); PMID 22666519 (Oxid Med Cell Longev 2012 review)
No standardized dosing protocols established for oral or injectable GHK (without copper) in humans
HighAbsence of evidence on ClinicalTrials.gov/PubMed; PMID 29986520 (review, no human dosing data reported)
Theoretical concern: broad gene modulation (4,000+ genes) could have unintended effects not yet characterized
TheoreticalPMID 22937864 (GHK recapitulates TGF-beta-induced gene expression in human fibroblasts); PMID 29986520
Interaction summary(8)
Rated by direction with this peptide
Copper chelation therapy (penicillamine, trientine, tetrathiomolybdate) / Wilson disease
CautionModerateGHK-Cu is a copper delivery vehicle and directly opposes the therapeutic goal of chelation, making it a mechanism-based contraindication in Wilson disease or any copper-overload state under treatment. No clinical interaction report exists; severity is held at Moderate because typical topical copper exposure is small, but the direction of the conflict is unambiguous.
Mechanism-based (GHK-Cu is a copper carrier, PMID 26236730); no interaction study published
Copper supplements / high-copper multivitamins
CautionLowAdditive copper load, most relevant with large-area topical or any systemic use, since chronic copper excess causes GI intolerance and hepatic accumulation; single-application topical GHK-Cu delivers trivial copper by comparison.
Mechanism-based; NIH ODS copper fact sheet (ods.od.nih.gov/factsheets/Copper-HealthProfessional)
High-dose zinc supplementation
CautionTheoreticalZinc and copper compete for intestinal absorption via metallothionein induction and zinc can displace copper from peptide complexes in vitro, so sustained high-dose zinc could blunt copper-dependent GHK-Cu activity - never tested against GHK specifically.
Mechanism-based; NIH ODS zinc fact sheet (ods.od.nih.gov/factsheets/Zinc-HealthProfessional)
High-dose ascorbic acid (vitamin C)
CautionLowIn practice ascorbate reduces Cu(2+) to Cu(+), destabilizing the GHK-copper chelate and enabling Fenton-type redox reactions, so co-formulating or layering the two topically can inactivate the peptide and is pro-oxidant rather than antioxidant. The only 'synergy' evidence is old rodent implanted-tumor work with copper-peptide plus ascorbate, reported second-hand in review articles and with no human counterpart - too thin to label this interaction beneficial in a safety reference.
Redox chemistry of Cu-peptide/ascorbate systems; rodent tumor data described second-hand in PMID 29986520 (review)
Low-pH topicals: retinoids, alpha/beta hydroxy acids, high-concentration vitamin C serums
CautionLowAcidic vehicles and reducing agents destabilize the GHK-copper chelate and can cause irritation when layered, which is why formulation guidance separates GHK-Cu from these in time or product.
Formulation/stability rationale; Pharm Dev Technol 2016;21(2) (doi:10.3109/10837450.2014.979944)
Systemic corticosteroids
CautionTheoreticalGlucocorticoids suppress collagen synthesis and fibroblast activity and would be expected to blunt GHK's pro-repair signaling in wound-healing use, though no head-to-head study exists.
Mechanism-based; steroid impairment of wound healing is well established, the GHK interaction itself is unstudied
Antifibrotic therapy (pirfenidone, nintedanib) and fibrotic/keloid-prone conditions
CautionTheoreticalGHK reproduces a TGF-beta-driven expression program - the mechanism credited for its lung and skin repair effects - which runs directly counter to antifibrotic intent and is a plausible concern in active fibrosis or keloid formation.
PMID 22937864 (GHK recapitulates TGF-beta-induced gene expression in human fibroblasts); no clinical interaction data
Standard wound care (debridement, offloading, pressure-relieving footwear)
SynergisticLowThe positive diabetic ulcer RCT delivered topical GHK-Cu on top of an aggressive standardized wound protocol, so the demonstrated benefit is as an adjunct to, not a replacement for, conventional care.
PMID 17147644 (multicenter randomized evaluator-blinded placebo-controlled trial, standardized wound care in both arms)
Known risks(8)
Very limited human clinical data for GHK alone (most studies use GHK-Cu copper complex)
Research-grade GHK peptide may not meet pharmaceutical purity standards — quality varies among unregulated products sold online
Sensitive to carboxypeptidase degradation, particularly in wound environments — rapid breakdown limits bioavailability
Long-term systemic safety data in humans is lacking (no large-scale injectable trials)
Gene modulation data is primarily from Broad Institute Connectivity Map computational analysis, not all validated in vivo
GHK alone may have reduced efficacy compared to GHK-Cu for applications requiring copper delivery (antioxidant, wound healing)
No standardized dosing protocols established for oral or injectable GHK (without copper) in humans
Theoretical concern: broad gene modulation (4,000+ genes) could have unintended effects not yet characterized
Drug interactions(5)
Copper supplements
GHK has very high affinity for copper(II) ions. Co-administration with copper supplements could increase GHK-Cu formation and alter copper metabolism. May potentiate copper-related effects.
Chelating agents (penicillamine, trientine)
Copper chelators could compete with GHK for copper binding, potentially reducing formation of biologically active GHK-Cu complex and diminishing efficacy.
NSAIDs and anti-inflammatory drugs
GHK has intrinsic anti-inflammatory activity (suppresses TNF-alpha, IL-6, blocks NFkappaB). Additive anti-inflammatory effects possible. No adverse interactions reported.
Anticoagulants (warfarin, heparin)
GHK suppresses fibrinogen beta chain gene expression by -475%. Theoretical additive anticoagulant effect. Monitor coagulation parameters if co-administered.
Immunosuppressants
GHK modulates immune-related gene expression and inflammatory pathways. Potential for interaction with immunosuppressive therapy, though no clinical data exists.
Research & benefits
Evidence base
- Evidence Level
- Limited Clinical
- Total Studies
- 40
- Human Studies
- 6
Over 50 years of research since 1973 discovery. Broad Institute gene profiling confirms modulation of 4,000+ genes. Multiple 12-week placebo-controlled human trials for topical skin applications (using GHK-Cu). Extensive animal wound healing data across 5+ species. Anti-cancer and COPD gene reversal data from genomic analyses. Cognitive improvement in aged mice. Most clinical human studies used the copper-complexed form (GHK-Cu); GHK alone has strong in vitro and genomic evidence but fewer standalone human trials.
Researched for(10)
Rated by confidence in the evidence
Gene expression modulation (4,000+ genes)
LowDerived from one human cell-line gene expression dataset, mostly unvalidated experimentally.
PMID 29986520 (Pickart & Margolina, Int J Mol Sci 2018;19:1987, PMC6073405 - review); PMID 26236730 (BioMed Res Int 2015, PMC4508379 - review)
Wound healing and tissue regeneration
SpeculativeShown for the related compound GHK-Cu, not directly tested for copper-free GHK in humans.
No human trial of copper-free GHK for wound healing exists. PMID 17147644 (Mulder et al., Wound Repair Regen 1994;2:259-69) tested the copper complex GHK-Cu (as "lamin Gel"), a related but distinct molecule, in a single small, sponsor-affiliated, evaluator-blinded (not double-blind) trial never independently replicated. Support for copper-free GHK itself is limited to animal/in-vitro wound-repair studies (e.g. PMID 15803494, rat dermal wound model).
Anti-inflammatory action
LowReduces inflammatory markers in animal and cell studies, not yet tested in a human trial.
PMC9354777 (Front Mol Biosci 2022, GHK-Cu attenuates cigarette smoke-induced pulmonary emphysema and inflammation, mouse + A549 cells); PMID 26236730 (review)
Neuroprotection and cognitive support
LowGene-expression studies and preliminary aged-mouse learning results support further research; human cognitive benefit remains unproven.
PMID 28212278 (Brain Sci 2017;7:20, Effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline); PMID 22666519 (Pickart et al., Oxid Med Cell Longev 2012 - review)
Antioxidant activity
LowBlocks oxidative damage in lab and animal studies, mostly via the copper-bound form, no human trials.
PMID 22666519 (Oxid Med Cell Longev 2012 - review); PMC9354777 (Front Mol Biosci 2022, mouse Nrf2 data); PMID 26236730 (review)
Anti-cancer gene modulation
SpeculativeCell culture and computational gene data only, no animal tumor confirmation or human studies.
PMID 29986520 (Int J Mol Sci 2018 review; carries the CMap colon-cancer and rodent tumor claims); J Analytical Oncology 2014 (Pickart, GHK induces anti-cancer expression of caspase, growth regulatory and DNA repair genes - non-PubMed-indexed journal); Matalka et al. 2012, J Nanomed Nanotechnol 3:144 (SH-SY5Y apoptosis; non-indexed journal)
COPD and lung tissue repair
LowReverses emphysema gene signatures in human lung tissue and cells, no COPD clinical trial yet.
PMID 22937864 (Genome Med 2012, PMC4064320); PMC9354777 (Front Mol Biosci 2022)
Skin anti-aging and stem cell activation
LowCited human cosmetic trials are described only in industry reviews, not independently published data.
PMID 26236730 (BioMed Res Int 2015, PMC4508379 - review by the developer, describes the clinical studies second-hand); PMID 29986520 (Int J Mol Sci 2018 review)
DNA repair support
SpeculativeBased on gene-expression analysis in cell culture only, no functional DNA-damage testing done.
J Analytical Oncology 2014 (Pickart, GHK, the human skin remodeling peptide, induces anti-cancer expression of numerous caspase, growth regulatory, and DNA repair genes - non-indexed, unverified); PMID 29986520 (Int J Mol Sci 2018 review)
Anxiolytic and anti-aggression effects
SpeculativeSmall single-lab rat studies only, unreplicated and unverified, no human data exists.
Bobyntsev et al., Bull Exp Biol Med 2015 (Anxiolytic effects of Gly-His-Lys peptide and its analogs), doi:10.1007/s10517-015-2847-3
Benefits(10)
Gene expression modulation (4,000+ genes)
Broad Institute Connectivity Map analysis; Pickart & Margolina 2018 (IJMS). Stimulates 1,569 genes and suppresses 583 at >=50% threshold. Resets pathological gene expression patterns toward health.
Wound healing and tissue regeneration
Multiple animal studies in rabbits, rats, mice, pigs, and dogs. Stimulates collagen, elastin, glycosaminoglycan synthesis. Increases blood vessel and nerve outgrowth. GHK-Cu collagen dressing increased collagen 9-fold in healthy rats.
Anti-inflammatory action
Reduces TNF-alpha-induced IL-6 secretion in dermal fibroblasts. Blocks NFkappaB p65 and p38 MAPK activation. Suppresses fibrinogen beta chain gene expression by -475%. Pickart et al. 2018.
Neuroprotection and cognitive support
Pickart et al. 2017 (Brain Sciences). Upregulates 408 and downregulates 230 genes relevant to neuronal function. Aged mice (28 months) at 10 mg/kg showed improved cognitive performance. Stimulates NGF, NT-3, NT-4 production.
Antioxidant activity
Blocks Cu(2+)-dependent LDL oxidation with superior efficacy vs SOD1. GHK:Cu(2+) reduces iron release from ferritin by 87%. Pickart & Margolina 2018.
Anti-cancer gene modulation
Hong et al. 2010 used Connectivity Map analysis of 70% of a 54-gene cancer signature to predict expression reversal, identifying GHK as 1 of only 2 compounds (of 1,309 tested) predicted to downregulate metastatic colon cancer genes. Upregulates 10 caspase genes.
COPD and lung tissue repair
Multi-institutional research (Boston University, University of Groningen, UBC, UPenn). Reverses expression of 127 genes altered in COPD. Restores lung fibroblast contractile function. Increases integrin beta 1.
Skin anti-aging and stem cell activation
12-week placebo-controlled trials (71, 41, 67 women). Improved skin laxity, density, thickness, reduced wrinkles. Thigh study: 70% improved collagen vs 50% vitamin C, 40% retinoic acid. Increases epidermal stem cell markers (p63, integrins).
DNA repair support
Connectivity Map analysis: 47 DNA repair genes stimulated, 5 suppressed. Irradiated fibroblasts (5000 rad) treated with GHK (10^-9 M) recovered growth dynamics similar to non-irradiated controls. Pickart et al. 2015.
Anxiolytic and anti-aggression effects
Reduces pain response in mice at 0.5 mg/kg. Anxiolytic in rats at 0.5 microg/kg. Reduces aggression 5-fold in conflict scenarios. Estimated human anti-aggression dose: ~35 micrograms. Pickart & Margolina 2018.
Key studies(6)
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Comprehensive ReviewN/A (review of multiple studies)Pickart L, Vasquez-Soltero JM, Margolina A
BioMed Research International
2015
GHK modulates 4,000+ human genes. Effective at 1-10 nM for wound healing. Estimated human therapeutic dose: 100-200 mg. Very safe with no adverse events across decades of use.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Review with gene expression analysisN/A (gene profiling data analysis)Pickart L, Margolina A
International Journal of Molecular Sciences
2018
31.2% of human genes show >=50% expression change. 1,569 genes stimulated, 583 suppressed. GHK upregulates 10 caspase genes, 47 DNA repair genes, 41 ubiquitin proteasome genes. Suppresses fibrinogen by -475%. Anti-aggression at ~35 microg human dose.
The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline
Genomic analysis and literature reviewN/A (Connectivity Map gene analysis)Pickart L, Vasquez-Soltero JM, Margolina A
Brain Sciences
2017
GHK upregulates 408 and downregulates 230 genes relevant to neuronal function. Top gene: OPRM1 at +1,294%. Stimulates NGF, NT-3, NT-4. Proposed for Alzheimer's and Parkinson's therapy.
The potential of GHK as an anti-aging peptide
Review with animal dataN/A (review; includes mouse studies)Dou Y, Lee A, Zhu L, Morton J, Ladiges W
Aging Pathobiology and Therapeutics
2020
Aged mice (28 months) treated with GHK at 10 mg/kg showed improved cognitive performance. GHK partially reverses cognitive impairment by targeting anti-inflammatory and epigenetic pathways.
A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics
Genome-wide gene expression profiling1,309 bioactive compounds screenedHong Y, Downey T, Eu KW, Koh PK, Cheah PY
Clinical and Experimental Metastasis
2010
A Connectivity Map query using 70% of a 54-gene metastatic colon cancer signature identified GHK as 1 of only 2 compounds predicted to reverse that expression pattern.
The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health
ReviewN/A (comprehensive review)Pickart L, Vasquez-Soltero JM, Margolina A
Oxidative Medicine and Cellular Longevity
2012
GHK-Cu blocks Cu(2+)-dependent LDL oxidation with superior efficacy to SOD1. Reduces iron release from ferritin by 87%. Comprehensive overview of antioxidant and cognitive protection mechanisms.
Regulation & availability
Why researchers look at it
Broad Institute genomic analysis revealed this simple three-amino-acid peptide modulates expression of over 4,000 human genes — roughly 31% of the genome — spanning tissue repair, inflammation, and remodeling pathways. Blood levels decline approximately 60% between age 20 and 60, correlating with reduced healing capacity. While most clinical evidence pertains to the copper-bound form (GHK-Cu) in topical applications, genomic data showing reversal of disease signatures in COPD and cancer suggests systemic anti-aging potential only beginning to be explored.
- Estimated cost
- $15-50/mo in OTC skincare (copper peptide products)
- FDA status
- Not FDA-approved. GHK (without copper) has no FDA drug designation. It is not classified as a dietary supplement ingredient with an NDI notification. The copper-complexed form (GHK-Cu) is used in OTC cosmetics (as Copper Tripeptide-1) and in compounded injectables, but the FDA has noted concerns about injectable peptide impurities and immunogenicity. GHK alone is primarily used in research contexts.
- WADA status
- Not specifically named in the 2026 WADA Prohibited List. Endogenous occurrence does not establish permission to administer it. S0 covers unapproved pharmacological substances; compound-specific athletic clearance was not confirmed.
- Prescribability
- Not FDA-approved as a drug. Most clinical and therapeutic applications use the copper-complexed form (GHK-Cu) rather than GHK alone. It is not regulated as a prescription drug.
- Availability
- It is not widely sold as a consumer supplement or therapeutic product in its copper-free form. Most commercial and clinical products use the copper-complexed form (GHK-Cu). It is described as 'abundantly available at low cost in bulk quantities.' Not available as a prescription medication. Topical formulations primarily use GHK-Cu. Injectable GHK-Cu is excluded from 503A Category 1 and is on FDA's safety-risk list of withdrawn nominations. Some clinics advertise injections, which does not establish eligibility.
International status
EU
Not approved
US
GHK is not FDA-approved and is not eligible for compounding in the US.
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(9)
- 1973GHK first isolated from human plasma by Loren Pickart as a factor causing old liver tissue to synthesize proteins like younger tissue.
- 1980sGHK-Cu (copper complex) characterized and early wound healing studies begin.
- 2010Broad Institute Connectivity Map analysis reveals GHK modulates 4,000+ human genes — paradigm shift from copper-delivery to gene modulation mechanism.
- 2010Hong et al. identify GHK as 1 of 2 compounds (of 1,309 screened) capable of downregulating metastatic colon cancer genes.
- 2012Pickart et al. publish comprehensive review on GHK-Cu in oxidative stress prevention and cognitive health (Oxidative Medicine and Cellular Longevity).
- 2015Major review published in BioMed Research International establishing GHK as a natural modulator of multiple cellular pathways.
- 2017Pickart et al. publish analysis of GHK effects on nervous system gene expression in Brain Sciences, proposing neuroprotective applications.
- 2018Updated review by Pickart & Margolina in IJMS with comprehensive gene data: 1,569 genes stimulated, 583 suppressed at >=50% threshold.
- 2020Dou et al. (Aging Pathobiology and Therapeutics) demonstrate GHK improves cognitive performance in aged mice at 10 mg/kg, targeting anti-inflammatory and epigenetic pathways.
Sources & FAQs
Research sources(7)
- https://pubmed.ncbi.nlm.nih.gov/26236730/
- https://pubmed.ncbi.nlm.nih.gov/29986520/
- https://pubmed.ncbi.nlm.nih.gov/28212278/
- https://pubmed.ncbi.nlm.nih.gov/35083444/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3359723/
Frequently asked questions(5)
What is the difference between GHK and GHK-Cu?
GHK is the base tripeptide (glycyl-L-histidyl-L-lysine) without copper. GHK-Cu is the same peptide complexed with a copper(II) ion. In vivo, GHK readily binds available copper to form GHK-Cu. Most clinical applications use GHK-Cu. However, since 2010, research shows GHK alone can modulate gene expression independently of copper delivery, suggesting the base peptide has intrinsic biological activity beyond serving as a copper carrier.
Why do GHK levels decline with age?
Plasma GHK levels average ~200 ng/mL at age 20 but decline to ~80 ng/mL by age 60 — a 60% reduction. The exact cause is not fully understood but correlates with decreased regenerative capacity. GHK is released from breakdown of extracellular matrix proteins (collagen, SPARC), so age-related changes in protein turnover may contribute.
Can GHK alone (without copper) provide therapeutic benefits?
Emerging evidence suggests yes. While most studies use GHK-Cu, the Broad Institute Connectivity Map data shows GHK alone modulates 4,000+ genes. Some in vitro studies demonstrate copper-free GHK retains stem cell recovering effects and gene modulation activity. However, for most therapeutic applications, GHK-Cu is preferred as the copper complex enhances certain mechanisms including antioxidant activity and cellular copper delivery.
How many genes does GHK affect?
At the >=50% expression change threshold, GHK affects 31.2% of human genes — stimulating 1,569 and suppressing 583. At lower thresholds, over 4,000 genes are modulated. Key pathways affected include DNA repair (47 genes up), ubiquitin proteasome system (41 genes up), caspase/apoptosis (10 genes up), and neuronal function (408 up, 230 down).
Is GHK safe?
GHK and GHK-Cu have an excellent safety record. No adverse events have been reported across decades of cosmetic use and wound healing studies. The peptide is naturally occurring in human plasma. Cell studies show no irritation or sensitization. Long-term safety data for systemic (injectable) use is limited, however.